BioWorld-Insight-2010-02-15
Safety Brouhaha Tests 'Mettle' of Feraheme After Downgrade
Celera's Hidden Treasure: A 'Royal' Road to Payoff?
Last week, the Biotechnology Value Fund (BVF) proposed that Celera Corp. separate its low margin diagnostics business from its potentially high-margin drug royalty stream.

